How Can the Liquid Biopsy Market Realize Its $30B Potential?

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
The liquid biopsy market is expected to grow to as much as $30 billion by 2025. Many factors are propelling the growth of the field in coming years, including the advantages of liquid biopsy over solid tumor biopsy, rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives. This panel includes advanced and emerging leaders in the field from public and private companies who will together discuss growth factors as well as how the field is overcoming clinical utility challenges, demonstrating sensitivity and specificity of liquid biopsy tests and establishing clarity in regard to reimbursement and regulation.
Speakers
photo
Chief Executive Officer
Thrive Earlier Detection Corp.
photo
President and CEO
Lynx Biosciences
photo
Chief Executive Officer
Foundation Medicine
photo
Chief Operating Officer
Immunis.AI